Zobrazeno 1 - 10
of 19
pro vyhledávání: '"Julia Vaubel"'
Autor:
Lisa Zimmer, Julia Vaubel, Peter Mohr, Axel Hauschild, Jochen Utikal, Jan Simon, Claus Garbe, Rudolf Herbst, Alexander Enk, Eckhart Kämpgen, Elisabeth Livingstone, Leonie Bluhm, Rainer Rompel, Klaus G Griewank, Michael Fluck, Bastian Schilling, Dirk Schadendorf
Publikováno v:
PLoS ONE, Vol 10, Iss 3, p e0118564 (2015)
Up to 50% of patients with uveal melanoma (UM) develop metastatic disease with limited treatment options. The immunomodulating agent ipilimumab has shown an overall survival (OS) benefit in patients with cutaneous metastatic melanoma in two phase III
Externí odkaz:
https://doaj.org/article/2ff3e96d807047c3a0d2ce8d8353dfe0
Autor:
Caroline J Voskens, Simone M Goldinger, Carmen Loquai, Caroline Robert, Katharina C Kaehler, Carola Berking, Tanja Bergmann, Clemens L Bockmeyer, Thomas Eigentler, Michael Fluck, Claus Garbe, Ralf Gutzmer, Stephan Grabbe, Axel Hauschild, Rüdiger Hein, Gheorghe Hundorfean, Armin Justich, Ullrich Keller, Christina Klein, Christine Mateus, Peter Mohr, Sylvie Paetzold, Imke Satzger, Dirk Schadendorf, Marc Schlaeppi, Gerold Schuler, Beatrice Schuler-Thurner, Uwe Trefzer, Jens Ulrich, Julia Vaubel, Roger von Moos, Patrik Weder, Tabea Wilhelm, Daniela Göppner, Reinhard Dummer, Lucie M Heinzerling
Publikováno v:
PLoS ONE, Vol 8, Iss 1, p e53745 (2013)
Ipilimumab, a cytotoxic T-lymphocyte antigen-4 (CTLA-4) blocking antibody, has been approved for the treatment of metastatic melanoma and induces adverse events (AE) in up to 64% of patients. Treatment algorithms for the management of common ipilimum
Externí odkaz:
https://doaj.org/article/1e9dff99dd604582ac2c2c7a3f9fad75
Publikováno v:
Journal of the European Academy of Dermatology and Venereology. 28:1685-1689
Background Epidermal growth factor receptor inhibitors (EGFRi) and MEK inhibitors (MEKi) are notorious for causing papulopustular rash. Treatment recommendations from studies and expert panels include, amongst others, oral tetracyclines. The efficacy
Publikováno v:
Annals of Oncology. 23:x104-x108
Immunotherapy using unspecific modulators has a long tradition in the adjuvant treatment of stage II/III melanoma. Interferon has shown a consistent effect on relapse-free survival independent of interferon dosage and duration. The results of the ame
Publikováno v:
JDDG: Journal der Deutschen Dermatologischen Gesellschaft. 10:475-487
Publikováno v:
JDDG: Journal der Deutschen Dermatologischen Gesellschaft. 10:475-486
The discovery of specific gene mutations, termed "driver mutations", in different tumors has brought personalized medicine into the focus of cancer treatment. Targeted treatment agents generally are administered orally and have a tolerable adverse ev
Publikováno v:
JDDG: Journal der Deutschen Dermatologischen Gesellschaft. 10:319-325
Autor:
Sarah Piel, Lisa Huptas, Elvir Cesko, Joachim Dissemond, Nadine Voshege, Thomas Jansen, Dirk Schadendorf, Julia Vaubel, Andreas Körber
Publikováno v:
hautnah dermatologie. 26:220-224
Publikováno v:
Oncology Letters. 1:237-241
Although adjuvant high-dose interferon α-2b therapy significantly improves recurrence-free survival vs. observation in high-risk resected melanoma, the overall survival benefit is presently unclear. Pegylation of interferon α-2b (peginterferon α-2
Autor:
Peter Mohr, Jochen Utikal, Bastian Schilling, Alexander Enk, Lisa Zimmer, Jan C. Simon, Rudolf A. Herbst, Klaus G. Griewank, Leonie Bluhm, Axel Hauschild, Elisabeth Livingstone, Dirk Schadendorf, Rainer Rompel, Eckhart Kämpgen, Michael Fluck, Julia Vaubel, Claus Garbe
Publikováno v:
PLoS ONE, Vol 10, Iss 3, p e0118564 (2015)
PLoS ONE
PLoS ONE
Purpose Up to 50% of patients with uveal melanoma (UM) develop metastatic disease with limited treatment options. The immunomodulating agent ipilimumab has shown an overall survival (OS) benefit in patients with cutaneous metastatic melanoma in two p